A detailed history of Erste Asset Management Gmb H transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Erste Asset Management Gmb H holds 120,000 shares of ENTA stock, worth $757,200. This represents 0.01% of its overall portfolio holdings.

Number of Shares
120,000
Holding current value
$757,200
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $16.54 $1.21 Million - $1.98 Million
120,000 New
120,000 $1.24 Billion
Q4 2023

Nov 26, 2024

BUY
$8.18 - $10.78 $208,590 - $274,890
25,500 Added 26.98%
120,000 $1.13 Billion
Q1 2023

Nov 26, 2024

BUY
$38.82 - $54.59 $776,400 - $1.09 Million
20,000 Added 26.85%
94,500 $3.79 Billion
Q4 2022

Nov 26, 2024

BUY
$40.77 - $53.73 $815,400 - $1.07 Million
20,000 Added 26.85%
94,500 $4.4 Billion
Q3 2022

Nov 26, 2024

SELL
$48.29 - $71.27 $2.2 Million - $3.24 Million
-45,500 Reduced 37.92%
74,500 $3.88 Billion
Q2 2022

Nov 26, 2024

SELL
$38.13 - $76.93 $1.73 Million - $3.5 Million
-45,500 Reduced 37.92%
74,500 $3.51 Billion
Q1 2022

Nov 22, 2024

BUY
$56.06 - $74.11 $4.18 Million - $5.52 Million
74,500 New
74,500 $5.25 Billion
Q4 2020

Nov 22, 2024

SELL
$41.16 - $47.47 $255,191 - $294,314
-6,200 Closed
0 $0
Q3 2020

Nov 22, 2024

SELL
$43.36 - $53.53 $4.93 Million - $6.09 Million
-113,800 Reduced 94.83%
6,200 $278 Million
Q4 2019

Nov 22, 2024

SELL
$57.95 - $66.61 $6.59 Million - $7.58 Million
-113,800 Reduced 94.83%
6,200 $388 Million
Q1 2019

Nov 22, 2024

SELL
$69.08 - $105.66 $7.86 Million - $12 Million
-113,800 Reduced 94.83%
6,200 $591 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $131M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.